Rationale and practice of testing chemotherapeutic agents for prostate cancer.
D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase / Q000378:metabolism; D000230:Adenocarcinoma / Q000201:enzymology / Q000473:pathology; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D001119:Arginase / Q000378:metabolism; D004273:DNA, Neoplasm / Q000378:metabolism; D004341:Drug Evaluation / Q000379:methods*; D006801:Humans; D008297:Male; D009374:Neoplasms, Experimental / Q000473:pathology; D009924:Organ Culture Techniques; D011471:Prostatic Neoplasms / Q000201:enzymology / Q000473:pathology; D011869:Radioligand Assay; D051381:Rats; D011944:Receptors, Androgen / Q000378:metabolism; D013936:Thymidine / Q000378:metabolism; D015032:Zinc / Q000378:metabolism
D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D011944:Receptors, Androgen; D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase; D001119:Arginase; D015032:Zinc; D013936:Thymidine